This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Hiromatsu Y, Eguchi H, Tani J, et al. Graves’ ophthalmopathy: epidemiology and natural history. Intern Med. 2014;53(5):353–360.Search in Google Scholar
Bartalena L, Piantanida E, Gallo D, et al. Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy. Front Endocrinol (Lausanne). 2020;11(November):1-10.Search in Google Scholar
Stan MN, Bahn RS. Risk factors for development or deterioration of Graves’ ophthalmopathy. Thyroid. 2010;20(7):777-783.Search in Google Scholar
Bartalena L, Marcocci C, Pinchera A. Graves ’ophthalmopathy: A preventable disease? Eur J Endocrinol. 2002;146(4):457-461.Search in Google Scholar
Bahn RS. TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves’ ophthalmopathy. J Endocrinol Invest. 2004;27(3):216-220.Search in Google Scholar
Krieger CC, Place RF, Bevilacqua C, et al. TSH/IGF-1 receptor cross talk in Graves’ ophthalmopathy pathogenesis. J Clin Endocrinol Metab. 2016;101(6):2340-2347.Search in Google Scholar
Łacheta D, Miśkiewicz P, Głuszko A, et al. Immunological Aspects of Graves‘ Ophthalmopathy. Biomed Res Int. 2019 Nov 12;2019:7453260.Search in Google Scholar
Khong JJ, McNab A, Ebeling PR, et al. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol. 2015;100(1):142-150.Search in Google Scholar
Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, Graves’ Disease, and Thyroid-Associated Ophthalmopathy. Thyroid. 2008;18(9):953-958.Search in Google Scholar
Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves‘ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves‘ orbitopathy. Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67.Search in Google Scholar
Kahaly GJ, Petrak F, Hardt J, et al. Psychosocial morbidity of Graves’ orbitopathy. Clin Endocrinol (Oxf). 2005;63(4): 395-402.Search in Google Scholar
Siderova M. Thyroid-associated ophthalmopathy. Varna: Steno, 2017, 63-72.Search in Google Scholar
Lanzolla G, Vannucchi G, Ionni I, et al. Cholesterol Serum Levels and Use of Statins in Graves‘ Orbitopathy: A New Starting Point for the Therapy. Front Endocrinol (Lausanne). 2020;10(January):1-8.Search in Google Scholar
Sabini E, Mazzi B, Profi lo MA, et al. High Serum Cholesterol is a Novel Risk Factor for Graves’ Orbitopathy: Results of a Cross-Sectional Study. Thyroid. 2018;28(3):386-394.Search in Google Scholar
Ismailova DS, Fedorov AA, Grusha YO. Ocular surface changes in thyroid eye disease. Orbit. 2013;32(2):87-90.Search in Google Scholar
Ujhelyi B, Gogolak P, Erdei A, et al. Graves’ Orbitopathy Results in Profound Changes in Tear Composition: A Study of Plasminogen Activator Inhibitor-1 and Seven Cytokines. Thyroid. 2012;22(4):407-414.Search in Google Scholar
Laurance K, John P, Nadine F. The use of ACTH and cortisone in the treatment and in the differential diagnosis of malignant exophthalmos: a preliminary report. Ann Intern Med. 1953;38(5):913-918.Search in Google Scholar
Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;55:9-269.Search in Google Scholar
Nagayama Y, Izumi M, Kiriyama T, et al. Intravenous Methylprednisolone Pulse Therapy. Acta Endocr (Copenh).1984; 116: 513-518Search in Google Scholar
Macchia PE, Bagattini M, Lupoli G, et al. High-dose intravenous corticosteroid therapy for Graves’ ophthalmopathy. J Endocrinol Invest. 2001;24(3):152-158.Search in Google Scholar
Bromberg N, Romaldini J, Sgarbi J, et al. Pulse therapy in Graves’ ophthalmopathy: improvement of eye signs and ophtalmic immunoglobulins. AA Balkema Publ Hague, 1991.1991;353-357.Search in Google Scholar
Romaldini J, Werner R, Farah C, et al. Active Graves’ ophthalmopathy (GO) treatment with prolonged methylprednisolone therapy. Thyroid 1993. 1993;3-10.Search in Google Scholar
Matejka G, Vergès B, Vaillant G, et al. Intravenous methylprednisolone pulse therapy in the treatment of Graves’ ophthalmopathy. Horm Metab Res. 1998;30(2):93-8.Search in Google Scholar
van Geest RJ, Sasim I V, Koppeschaar HPF, et al. Methylprednisolone pulse therapy for patients with moderately severe Graves’ orbitopathy: A prospective, randomized, placebo-controlled study. Eur J Endocrinol. 2008;158(2):229-237.Search in Google Scholar
Kahaly GJ, Pitz S, Hommel G, et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90(9):5234-5240.Search in Google Scholar
Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the Effectiveness and Tolerability of Intravenous or Oral Glucocorticoids Associated with Orbital Radiotherapy in the Management of Severe Graves ’ Ophthalmopathy : Results of a Prospective, Single-Blind, Randomized Study. J Clin Endocrinol Metab. 2001;86(8):3562-3567.Search in Google Scholar
Aktaran Ş, Akarsu E, Erbağci İ, et al. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathy. Int J Clin Pract. 2006;61(1):45-51.Search in Google Scholar
Bartalena L, Krassas GE, Wiersinga W, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97(12):4454-4463.Search in Google Scholar
Bartalena L, Veronesi G, Krassas GE, et al. Does early response to intravenous glucocorticoids predict the fi nal outcome in patients with moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest. 2017;40(5):547-553.Search in Google Scholar
Owecki M, Sowiński J. Acute myocardial infarction during high-dose methylprednisolone therapy for Graves’ ophthalmopathy. Pharm World Sci. 2006;28(2):73-75.Search in Google Scholar
Gursoy A, Cesur M, Erdogan MF, et al. New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves’ ophthalmopathy. Endocrine. 2006;29(3):513-516.Search in Google Scholar
Le Moli R, Baldeschi L, Saeed P, et al. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves’ ophthalmopathy. Thyroid. 2007;17(4):357-362.Search in Google Scholar
Marinò M, Morabito E, Altea MA, et al. Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves’ ophthalmopathy treated successfully with glucocorticoids themselves. J Endocrinol Invest. 2005;28(5):280-284.Search in Google Scholar
Salvi M, Vannucchi G, Sbrozzi F, et al. Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto’s thyroiditis: Case report. Thyroid. 2004;14(8):631-634.Search in Google Scholar
Marinól M, Morabito E, Brunetto MR, et al. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid. 2004;14(5):403-406.Search in Google Scholar
Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid. 2000;10(6):521-524.Search in Google Scholar
Lendorf ME, Rasmussen ÅK, Fledelius HC, et al. Cardiovascular and cerebrovascular events in temporal relationship to intravenous glucocorticoid pulse therapy in patients with severe endocrine ophthalmopathy. Thyroid. 2009;19(12):1431-1432.Search in Google Scholar
Zang S, Ponto KA, Kahaly GJ. Intravenous glucocorticoids for Graves’ orbitopathy: Efficacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320-332.Search in Google Scholar
Gontarz-Nowak K, Szychlińska M, Matuszewski W, et al. Current Knowledge on Graves’ Orbitopathy. J Clin Med. 2020;10(1):16-20.Search in Google Scholar
Bartalena L, Marcocci C, Pinchera A. Orbital Radiotherapy for Graves’ Ophthalmopathy. J Clin Endocrinol Metab. 2004;89(1):13-24.Search in Google Scholar
Bartalena L, Pinchera A, Marcocci C. Management of Graves’ Ophthalmopathy : Reality and Perspectives. Endocr Rev. 2007;21(2):168-199.Search in Google Scholar
Nakahara H, Noguchil S, Murakami N, et al. Graves Ophthalmopathy: MR Evaluation of 10-Gy versus 24-Gy Irradiation combined with Systemic Corticosteroids. Thera. 1996;196(3):857-862.Search in Google Scholar
Pitz S, Kahaly GJ, Ro H, et al. Low- Versus High-Dose Radiotherapy for Graves’ Ophthalmopathy : A Randomized, Single Blind Trial. J Clin Endocrinol Metab. 2016;85(1):102–108.Search in Google Scholar
Donaldson SS, Bagshaw MA, Kriss JP. Supervoltage orbital radiotherapy for Graves’ ophthalmopathy. J Clin Endocrinol Metab. 1973;37(2):276-285.Search in Google Scholar
Gorman C, Garrity J, Fatourechi V. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology. 2001;108(9):1523-1534.Search in Google Scholar
Mourits MP, Van Kempen-Harteveld ML, García MB, et al. Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study. Lancet. 2000;355(9214):1505-1509.Search in Google Scholar
Gabrovski R, Hristosov K, Siderova M, et al. Co orbital radiotherapy in Graves’ opthlamopathy. Scripta scientifica medica. 2013;45(4):41-45.Search in Google Scholar
Prummel MF, Berghout A, Wiersinga WM, et al. Randomised double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet. 1993;342(8877):949-954.Search in Google Scholar
Bartalena L, Marcocci C, Chiovato L, et al. Orbital Cobalt Irradiation combined with Systemic Corticosteroids for Graves’ Ophthalmopathy: Comparison with Systemic Corticosteroids Alone. J Clin Endocrinol Metab. 1983;56(6):1139-1144.Search in Google Scholar
Marcocci C, Bartalena L, Bogazzi F, et al. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest. 1991;14(10):853-860.Search in Google Scholar
Tanda ML, Bartalena L. Efficacy and safety of orbital radiotherapy for Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97(11):3857-3865.Search in Google Scholar
Matthiesen C, Thompson JS, Thompson D, et al. The efficacy of radiation therapy in the treatment of Graves’ orbitopathy. Int J Radiat Oncol Biol Phys. 2012;82(1):117-123.Search in Google Scholar
Oeverhaus M, Witteler T, Lax H, et al. Combination Therapy of Intravenous Steroids and Orbital Irradiation is More Effective Than Intravenous Steroids Alone in Patients with Graves’ Orbitopathy. Horm Metab Res. 2017;49(10):739-747.Search in Google Scholar
Kim JW, Han SH, Son BJ, et al. Efficacy of combined orbital radiation and systemic steroids in the management of Graves’ orbitopathy. Graefe’s Arch Clin Exp Ophthalmol. 2016;254(5):991-998.Search in Google Scholar
Johnson JC, Parker JS, Eyre P. Graves’ Ophthalmopathy. J Am Vet Med Assoc. 2021;259(4):353-355.Search in Google Scholar
Marcocci C, Bartalena L, Rocchi R, et al. Long-term safety of orbital radiotherapy for Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2003;88(8):3561-3566.Search in Google Scholar
Wakelkamp IMMJ, Tan H, Saeed P, et al. Orbital irradiation for Graves’ ophthalmopathy: Is it safe? A long-term follow-up study. Ophthalmology. 2004;111(8):1557-62.Search in Google Scholar
Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2-3):85-118.Search in Google Scholar
Ye X, Bo X, Hu X, et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves’ orbitopathy. Clin Endocrinol (Oxf). 2017;86(2):247-255.Search in Google Scholar
Kahaly GJ, Riedl M, König J, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6(4):287-298.Search in Google Scholar
Orgiazzi J. Adding the Immunosuppressant Mycophenolate Mofetil to Medium-Dose Infusions of Methylprednisolone Improves the Treatment of Graves’ Orbitopathy. Clin Thyroidol. 2018;30(1):10-14.Search in Google Scholar
Tosato G, Pike SE. Cyclosporin in Autoimmune Disease. Lancet. 1985;325(8434):909-911.Search in Google Scholar
Bartalena L, Marcocci C, Pinchera A. Treating severe Graves’ ophthalmopathy. Baillieres Clin Endocrinol Metab. 1997;11(3):521-536.Search in Google Scholar
Weetman AP, McGregor AM, Ludgate M, et al. Cyclosporin improves Graves’ ophthalmopathy. Lancet. 1983;322(8):486-9.Search in Google Scholar
Kahaly GJ, Schrezennmeir J, Krause Um Schweikert B, et al. Cyclosporin and prednisone v. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest. 1986;16(5):415-422.Search in Google Scholar
Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med. 1989;321(20):1353-1359.Search in Google Scholar
Ginter A, Migliori ME. The Role of Biological Agents and Immunomodulators in Treatment Strategies for Thyroid Eye Disease: An Evidence-based Review. R I Med J. 2016;99(6):26-30.Search in Google Scholar
El Fassi D, Nielsen CH, Hasselbalch H, et al. Treatment- resistant severe, active Graves’ ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid. 2006;16:709-710.Search in Google Scholar
Salvi M, Vannucchi G, Campi I, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol. 2006;154(4):511-7.Search in Google Scholar
Salvi M, Vannucchi G, Currò N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves’ orbitopathy: A randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422-431.Search in Google Scholar
Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized Controlled Trial of Rituximab in Patients With Graves’ Orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432-441.Search in Google Scholar
Salvi M, Vannucchi G, Introna N, et al. Small Dose of Rituximab for Graves’ Orbitopathy: New Insights Into the Mechanism of Action. Arch Ophtalmol. 2012;130(1):2012-2014.Search in Google Scholar
Descotes J. Immunotoxicity of monoclonal antibodies. Landes Biosci. 2009;1(2):104-111.Search in Google Scholar
Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-1502.Search in Google Scholar
Wiersinga WM. Autoimmunity in Graves’ ophthalmopathy: The result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab. 2011;96(8):2386-2394.Search in Google Scholar
Smith TJ, Janssen J. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev. 2018;40(1):236-267.Search in Google Scholar
Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017;376(18):1748-1761.Search in Google Scholar
Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med. 2020;382(4):341-352.Search in Google Scholar
Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021;9(6):360-372.Search in Google Scholar
Kumar S, Leontovich A, Coenen MJ. Gene Expression Profiling of Orbital Adipose Tissue From Patients With Graves’ Ophthalmopathy: a Protein-1 in Orbital Adipogenesis. 2005;90(8):4730-4735.Search in Google Scholar
Jyonouchi SC, Valyasevi RW, Harteneck DA, et al. Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fi broblasts from patients with Graves’ ophthalmopathy. Thyroid. 2001;11(10):929-934.Search in Google Scholar
Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. Am J Ophthalmol. 2018;195:181-190.Search in Google Scholar
Pérez-Moreiras JV, Álvarez-López A, Gómez EC. Treatment of Active Corticosteroid-Resistant Graves’ Orbitopathy. Ophthal Plast Reconstr Surg. 2014;30(2):162-167.Search in Google Scholar
Pérez-Moreiras JV, Varela-Agra M, Prada-Sánchez MC, et al. Steroid-resistant Graves’ orbitopathy treated with tocilizumab in real-world clinical practice: A 9-year single-center experience. J Clin Med. 2021;10(4):1-18.Search in Google Scholar
Sánchez-Bilbao L, Martínez-López D, Revenga M, et al. Antiil-6 receptor tocilizumab in refractory graves’ orbitopathy: National multicenter observational study of 48 patients. J Clin Med. 2020;9(9):1-15.Search in Google Scholar
Perros P, Weightman DR, Crombie AL, et al. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh). 1990;122(1):8-12.Search in Google Scholar
Chalvatzis NT, Tzamalis AK, Kalantzis GK, et al Safety and efficacy of combined immunosuppression and orbital radiotherapy in thyroid-related restrictive myopathy: Two-center experience. Eur J Ophthalmol. 2014;24(6):953-959.Search in Google Scholar
Rajendram R, Taylor PN, Wilson VJ, et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(4):299-309.Search in Google Scholar
